StockData
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. (MRKR) stock

MRKRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 6/30
$0.84+0.01 (+0.97%)

Close on Nov 17, 2026Market cap $13.95MP/E –Yield –

Marker Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Marker Therapeutics's total assets was $14.59M at Jun 30, 2026. For fiscal 2025 it was $19.07M, down 13.4% from the year before. Over ten years it grew 11.1% a year on average. The highest annual figure on record is $68.14M in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$19.07M-13.4%
FY2024Dec 31, 2024$22.02M+28.6%
FY2023Dec 31, 2023$17.13M-50.2%
FY2022Dec 31, 2022$34.42M-49.5%
FY2021Dec 31, 2021$68.14M+49.4%
FY2020Dec 31, 2020$45.61M-1.6%
FY2019Dec 31, 2019$46.36M-25.4%
FY2018Dec 31, 2018$62.14M+1099.6%
FY2017Dec 31, 2017$5.18M-34.6%
FY2016Dec 31, 2016$7.92M+19.2%
FY2015Dec 31, 2015$6.65M+2860.8%
FY2014Dec 31, 2014$224.45K+191.4%
FY2013Dec 31, 2013$77.03K-11.8%
FY2012Dec 31, 2012$87.37K-71.6%
FY2011Dec 31, 2011$307.92K+164.5%
FY2010Dec 31, 2010$116.43K–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$14.59M-1.2%
Q1 FY2026Mar 31, 2026$17.43M+2.6%
Q4 FY2025Dec 31, 2025$19.07M-13.4%
Q3 FY2025Sep 30, 2025$21.73M+99.2%
Q2 FY2025Jun 30, 2025$14.77M+26.5%
Q1 FY2025Mar 31, 2025$16.99M+20.6%
Q4 FY2024Dec 31, 2024$22.02M+28.6%
Q3 FY2024Sep 30, 2024$10.91M-44.0%
Q2 FY2024Jun 30, 2024$11.68M-46.8%
Q1 FY2024Mar 31, 2024$14.09M-49.6%
Q4 FY2023Dec 31, 2023$17.13M-50.2%
Q3 FY2023Sep 30, 2023$19.49M-52.6%
Q2 FY2023Jun 30, 2023$21.96M-58.0%
Q1 FY2023Mar 31, 2023$27.94M-49.2%
Q4 FY2022Dec 31, 2022$34.42M-49.5%
Q3 FY2022Sep 30, 2022$41.11M-42.8%
Q2 FY2022Jun 30, 2022$52.32M-35.0%
Q1 FY2022Mar 31, 2022$54.96M-37.8%
Q4 FY2021Dec 31, 2021$68.14M+49.4%
Q3 FY2021Sep 30, 2021$71.94M+48.1%
Q2 FY2021Jun 30, 2021$80.47M+65.8%
Q1 FY2021Mar 31, 2021$88.36M+106.0%
Q4 FY2020Dec 31, 2020$45.61M-1.6%
Q3 FY2020Sep 30, 2020$48.57M-5.5%
Q2 FY2020Jun 30, 2020$48.52M-11.8%
Q1 FY2020Mar 31, 2020$42.89M-27.3%
Q4 FY2019Dec 31, 2019$46.36M-25.4%
Q3 FY2019Sep 30, 2019$51.40M+551.4%
Q2 FY2019Jun 30, 2019$55.00M+1776.9%
Q1 FY2019Mar 31, 2019$58.99M+1038.7%
Q4 FY2018Dec 31, 2018$62.14M+706.6%
Q2 FY2018Jun 30, 2018$7.89M-22.2%
Q1 FY2018Mar 31, 2018$2.93M-52.0%
Q4 FY2017Dec 31, 2017$5.18M-34.6%
Q3 FY2017Sep 30, 2017$7.70M-20.6%
Q2 FY2017Jun 30, 2017$10.14M–
Q1 FY2017Mar 31, 2017$6.11M–
Q4 FY2016Dec 31, 2016$7.92M–
Q3 FY2016Sep 30, 2016$9.70M–

More Marker Therapeutics figures

See a number that looks wrong?